versions of Zolgensma, one used in a Phase 1 study and another tested in Phase 3, according to the FDA. Had the agency known about the manipulation, it would have delayed the approval of Zolgensma, according to Dr. Wilson Bryan, the director of the FDA division that reviewed Novartiss gene therapy.